COPD

3M Drug Delivery Systems will be working to introduce its Intelligent Inhaler to the market by developing a partnership with pharmaceutical companies.

Medication targets the protein IL-33 that plays a role in asthma.

Caregivers need to carefully monitor comorbidities that accompany a COPD diagnosis.

Analysis of neutrophil behavior enhances understanding of chronic obstructive pulmonary disease.

There was a 210% increase in NTM occurrence in patients with COPD taking ICS.

Persistent VPC asthma was seen in 48% of patients in the TENOR II study.

Patients with COPD have less access to care, higher treatment costs, and lower standards of care.

The underlying mechanisms of the immune system may lead to new treatments for COPD and lupus.

Bacteria frequently found deep inside the lungs of chronic obstructive pulmonary disease patients.

Big data from social media may help anticipate emergency department visits for chronic conditions.

Bevespi Aerosphere is a twice-daily, fixed-dose dual bronchodilator combining a long-acting muscarcinic antagonist and a long-acting beta-2 agonist.

Bevespi Aerosphere is a twice-daily, fixed-dose dual bronchodilator.

The FDA has approved AstraZeneca's glycopyrrolate and formoterol fumarate (Bevespi Aerosphere) inhalation aerosol for long-term maintenance treatment for patients with chronic obstructive pulmonary disease.

Lack of social support among the leading risk factors for anxiety among COPD patients.

United States Preventive Services Task Force states screening for chronic obstructive pulmonary disease not be performed without symptoms of the disease.

Statins may reduce morbidity and/or mortality in COPD patients.

HO-1 offers an attractive therapeutic target for the treatment of inflammatory conditions.

The FDA has approved Utibron Neohaler oral inhalation powder for long-term maintenance treatment of airflow obstruction in patients with COPD.

Patients with chronic obstructive pulmonary disease have reductions in their brains' gray matter related to the processing of dyspnea, fear, and sensitivity to painful stimuli.

Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, discusses some important patient-related factors to consider when selecting among available inhalers.

Cardio selective beta blockers reduced the relative risk of COPD exacerbations in a recent study.

Cinqair is used with other medications for the maintenance treatment of severe asthma in patients aged 18 years or older.

Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, demonstrates proper technique for inhaler devices.

Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, discusses adverse effects associated with asthma and COPD treatments.

Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, discusses what pharmacists should know about CAT and mMRC scores.

Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, discusses how to classify symptom severity, assess control, and monitor therapy for asthma and chronic obstructive pulmonary disorder.

Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, discusses the current guidelines pharmacists should refer to when selecting respiratory medication inhalers and managing asthma and chronic obstructive pulmonary disorder.

Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, discusses what comorbid conditions to look out for among asthma and COPD patients.

Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, discusses what therapeutic options are available for managing asthma and chronic obstructive pulmonary disorder.

The role of pharmacists in the treatment of acute coronary syndrome, COPD, atrial fibrillation, heart failure, opioid-induced constipation, and type 2 diabetes.